Stay updated on Tresiba Long-term Use Post-marketing Clinical Trial
Sign up to get notified when there's something new on the Tresiba Long-term Use Post-marketing Clinical Trial page.

Latest updates to the Tresiba Long-term Use Post-marketing Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for Novo Nordisk’s Tresiba® post-marketing surveillance study, including its completed status and details on participants, study design, and safety outcomes.SummaryDifference35%

- Check18 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA sitewide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe page remains a 403 Forbidden error page, with the displayed site revision changing from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check46 days agoChange DetectedThe study record view is replaced by a 403 Forbidden message and a Home link, leaving the trial details unavailable.SummaryDifference0.5%

Stay in the know with updates to Tresiba Long-term Use Post-marketing Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tresiba Long-term Use Post-marketing Clinical Trial page.